Summary

The global gene transfer technologies market is projected to surpass USD 5.93 billion in 2029 from USD 3.73 billion in 2024, with a significant CAGR of 9.7%. Increasing demand for personalized medicines, along with advancements in cell and gene therapies, continues to grow and contribute to a rise in this market. In addition, the increased application of gene transfer technologies in vaccine development and cancer immunotherapy boosts the segmental growth.
“The viral vector gene transfer technologies segment accounted for the largest share in 2023.”
On the basis of mode, the gene transfer technologies market is further segmented into viral vector and non-viral vector. The viral vector segment is retrovirus, adenovirus, adeno associated virus (AAV) and other virus vector. The viral vector segment dominated the market in 2023, owing to superior safety and efficacy profile, minimal immunogenicity and advancements in AAV engineering.
“By application, the therapeutic application segment accounted for the largest share in the gene transfer technologies market.”
The application segment in the gene transfer technologies market is segmented into research application, therapeutic application and applications. The research application is segmented into drug discovery & development and other research application. Similarly the therapeutic application further divided into gene therapy, cell therapy, vaccines and other therapeutic application. The therapeutic application dominated the segment owing to advancements in gene transfer technologies, such as improved adeno-associated virus (AAV) & lentiviral vector and expanding application of gene therapy in cardiovascular, neurological and metabolic diseases.
“North America: the largest share of the gene transfer technologies market”
By region, the market is segment into North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. North America dominated the gene transfer technologies market in 2023 and likely continue dominance during the forecast period. Presence of dominant market players in gene transfer technologies companies in the region, strong base of gene transfer technologies manufacturers such as Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany) are some of the prominent factors acerating market growth.
In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the gene transfer technologies market.
The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%
Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), Qiagen (Netherlands), Sartorius AG (Germany), Bio-Rad Laboratories Inc. (US), Revvity (US), Agilent Technologies, Inc. (US), Genscript (US), Bio-Techne (US), Lonza (Switzerland), Takara Bio, Inc. (Japan), Promega Corporation (US), Oxford Biomedica plc (UK) and MaxCyte (US) ) are some of the major players operating in the gene transfer technologies market.
Research Coverage:
This research report categorizes the gene transfer technologiess market product (instruments, consumables, reagents,kits & assays and other products), mode (viral vector and non viral vector), method (ex vivo, in vivo and in vitro), application (research, therapeutic and orther application) end user (pharmaceutical & biotechnology companies, academic & research institutes and other end users) and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the gene transfer technologiess market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the gene transfer technologies market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the gene transfer technologies and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (Growing demand for personalized medicines and cell & gene therapies, Increased investments in gene therapy research, Expanding applications in vaccine development & cancer immunotherapy), restraints (High costs of gene transfer systems), opportunities (Advancements in gene editing technologies and nanotechnology, Integration with digital technologies such as Al and ML) and Challenges (Scalability of production).
• Product Development/Innovation: Detailed insights on maintaining a comprehensive and innovative product portfolio offering for gene transfer technologies.
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the gene transfer technologies market
• Competitive Assessment: Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), Qiagen (Netherlands), Sartorius AG (Germany) and among others in the market.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 48
1.1 STUDY OBJECTIVES 48
1.2 MARKET DEFINITION 48
1.3 STUDY SCOPE 49
1.3.1 MARKETS COVERED AND REGIONAL SCOPE 49
1.3.2 INCLUSIONS & EXCLUSIONS 50
1.3.3 YEARS CONSIDERED 50
1.3.4 CURRENCY CONSIDERED 51
1.4 STAKEHOLDERS 51
2 RESEARCH METHODOLOGY 52
2.1 RESEARCH DATA 52
2.1.1 SECONDARY DATA 52
2.1.2 PRIMARY DATA 53
2.2 MARKET ESTIMATION METHODOLOGY 55
2.2.1 MARKET ESTIMATION 55
2.2.2 INSIGHTS FROM PRIMARY EXPERTS 57
2.2.3 TOP-DOWN APPROACH 58
2.3 MARKET GROWTH RATE PROJECTION 59
2.4 DATA TRIANGULATION 61
2.5 RESEARCH ASSUMPTIONS 61
2.6 RESEARCH LIMITATIONS 62
2.7 RISK ANALYSIS 63
3 EXECUTIVE SUMMARY 64
4 PREMIUM INSIGHTS 69
4.1 GENE DELIVERY TECHNOLOGIES MARKET OVERVIEW 69
4.2 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION (2023) 70
4.3 GENE DELIVERY TECHNOLOGIES MARKET SHARE, BY MODE, 2024 VS. 2029 70
4.4 GENE DELIVERY TECHNOLOGIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 71
 
5 MARKET OVERVIEW 72
5.1 INTRODUCTION 72
5.2 MARKET DYNAMICS 72
5.2.1 DRIVERS 73
5.2.1.1 Growing demand for personalized medicine and cell & gene therapies 73
5.2.1.2 Increased investments in gene therapy research 74
5.2.1.3 Expanding applications in vaccine development & cancer immunotherapy 75
5.2.2 RESTRAINTS 75
5.2.2.1 High costs of gene delivery systems 75
5.2.3 OPPORTUNITIES 76
5.2.3.1 Advancements in gene editing technologies & nanotechnology 76
5.2.3.2 Integration with digital technologies such as AI & ML 76
5.2.4 CHALLENGES 77
5.2.4.1 Scalability of production 77
5.3 ECOSYSTEM ANALYSIS 78
5.3.1 PRODUCT PROVIDERS 78
5.3.2 END USERS 79
5.3.3 REGULATORY BODIES 79
5.4 TECHNOLOGY ANALYSIS 80
5.4.1 KEY TECHNOLOGIES 80
5.4.1.1 Microinjection 80
5.4.1.2 Electroporation 80
5.4.1.3 Sonoporation 81
5.4.2 COMPLEMENTARY TECHNOLOGIES 81
5.4.2.1 Gene editing technologies 81
5.4.2.2 Bioinformatics and computational tools 81
5.4.3 ADJCENT TECHNOLOGIES 82
5.4.3.1 Nanotechnology and nano-carriers 82
5.5 PRICING ANALYSIS 82
5.5.1 AVERAGE SELLING PRICE TREND OF REAGENTS/CONSUMABLES, BY KEY PLAYER 82
5.5.2 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY REGION 84
5.6 VALUE CHAIN ANALYSIS 84
5.7 SUPPLY CHAIN ANALYSIS 86
5.8 PATENT ANALYSIS 87
5.9 TRADE ANALYSIS 89
5.9.1 IMPORT DATA FOR MACHINES AND APPARATUS FOR ELECTROPLATING, ELECTROLYSIS OR ELECTROPHORESIS (HS CODE: 854330) 89
5.9.2 EXPORT DATA FOR MACHINES AND APPARATUS FOR ELECTROPLATING, ELECTROLYSIS OR ELECTROPHORESIS (HS CODE: 854330) 90
5.10 KEY CONFERENCES AND EVENTS, 2024–2025 90
5.11 REGULATORY LANDSCAPE 91
5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91
5.11.2 REGULATORY FRAMEWORK 93
5.11.2.1 North America 93
5.11.2.2 Europe 94
5.11.2.3 Asia Pacific 94
5.11.2.4 Rest of the World 95
5.12 PORTER’S FIVE FORCES ANALYSIS 96
5.12.1 THREAT OF NEW ENTRANTS 97
5.12.2 THREAT OF SUBSTITUTES 97
5.12.3 BARGAINING POWER OF BUYERS 97
5.12.4 BARGAINING POWER OF SUPPLIERS 97
5.12.5 INTENSITY OF COMPETITIVE RIVALRY 97
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 97
5.13.1 KEY STAKEHOLDERS 98
5.13.2 BUYING CRITERIA 99
5.14 INVESTMENT AND FUNDING SCENARIO 100
5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 101
5.16 IMPACT OF AI/GEN AI ON GENE DELIVERY TECHNOLOGIES MARKET 102
6 GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT 104
6.1 INTRODUCTION 105
6.2 REAGENTS, KITS, AND ASSAYS 105
6.2.1 INCREASING DEMAND FOR TRANSFECTION AND GENE EDITING TOOLS TO DRIVE MARKET GROWTH 105
6.3 CONSUMABLES 109
6.3.1 RISING R&D ACTIVITY TO SUPPORT DEMAND GROWTH 109
6.4 INSTRUMENTS 112
6.4.1 INCREASING ADOPTION OF ELECTROPORATION DEVICES TO DRIVE MARKET 112
6.5 OTHER PRODUCTS 116
7 GENE DELIVERY TECHNOLOGIES MARKET, BY MODE 119
7.1 INTRODUCTION 120
7.2 VIRAL VECTORS 120
7.2.1 RETROVIRUSES 124
7.2.1.1 Lentiviruses 127
7.2.1.1.1 Rising disease incidence to drive market 127
7.2.1.2 Other retroviruses 130
7.2.2 ADENOVIRUSES 133
7.2.2.1 Expansion of vaccination programs to propel market growth 133
7.2.3 ADENO-ASSOCIATED VIRUSES 137
7.2.3.1 Low immunogenicity of AAV vectors to support adoption 137
7.2.4 OTHER VIRAL VECTORS 140
7.3 NON-VIRAL VECTORS 143
7.3.1 CHEMICAL METHODS 147
7.3.2 LIPOSOME-MEDIATED 151
7.3.2.1 High efficiency and compatibility to drive market 151
7.3.3 CALCIUM PHOSPHATE 154
7.3.3.1 Increasing R&D in cell-based therapies to propel market growth 154
7.3.4 DEAE-DEXTRAN 158
7.3.4.1 Simplicity and cost-effectiveness to support adoption 158
7.3.5 CATIONIC POLYMERS 161
7.3.5.1 Advancements in cationic polymer technology to drive market 161
7.3.6 OTHER CHEMICAL METHODS 165
7.4 PHYSICAL METHODS 168
7.4.1 ELECTROPORATION 172
7.4.1.1 Rising demand for effective cell transfection technologies to drive market 172
7.4.2 MICROINJECTION 175
7.4.2.1 High accuracy and control and potential for tailored delivery to drive market 175
7.4.3 GENE GUNS 179
7.4.3.1 High efficiency of gene guns in transfecting various cell types to drive market 179
7.4.4 OTHER PHYSICAL METHODS 182
8 GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD 186
8.1 INTRODUCTION 187
8.2 IN VIVO 187
8.2.1 EMERGENCE OF MRNA-BASED VACCINES TO PROPEL IN VIVO GENE DELIVERY APPLICATIONS 187
8.3 EX VIVO 191
8.3.1 SUCCESSFUL COMMERCIALIZATION OF CAR T-CELL THERAPIES TO DRIVE THE EX VIVO GENE DELIVERY MARKET 191
8.4 IN VITRO 194
8.4.1 DATABASES MAJORLY CONTRIBUTE TO STORING GENE DELIVERY TECHNOLOGIES AND INTEGRATING OTHER OMICS DATABASES. 194
9 GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION 198
9.1 INTRODUCTION 199
9.2 THERAPEUTIC APPLICATIONS 199
9.2.1 GENE THERAPY 203
9.2.1.1 Increasing demand for personalized medicine to support market growth 203
9.2.2 CELL THERAPY 206
9.2.2.1 Rising government funding to propel market growth 206
9.2.3 VACCINES 209
9.2.3.1 Rising prevalence of infectious diseases to drive market growth 209
9.2.4 OTHER THERAPEUTIC APPLICATIONS 213
9.3 RESEARCH APPLICATIONS 216
9.3.1 DRUG DISCOVERY & DEVELOPMENT 220
9.3.1.1 Increased funding for gene therapy research to drive market growth 220
9.3.1.2 Cancer 224
9.3.1.2.1 Rising investment in cancer research to drive market 224
9.3.2 INFECTIOUS DISEASES 228
9.3.2.1 Rising incidence of infectious disease to drive market growth 228
9.3.3 GENETIC & NEUROLOGICAL DISORDERS 231
9.3.3.1 Rising burden of disorders to drive market 231
9.3.4 AUTOIMMUNE DISEASES 235
9.3.4.1 Growing prevalence of autoimmune disorders to ensure demand for therapeutic solutions 235
9.3.5 OTHER DISEASES 238
9.3.6 OTHER RESEARCH APPLICATIONS 242
9.4 OTHER APPLICATIONS 245
10 GENE DELIVERY TECHNOLOGIES MARKET, BY END USER 249
10.1 INTRODUCTION 250
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 250
10.2.1 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO DOMINATE MARKET 250
10.3 ACADEMIC & RESEARCH INSTITUTES 254
10.3.1 INCREASING R&D AND GROWING FUNDING AND PARTNERSHIPS TO PROMOTE MARKET GROWTH 254
10.4 OTHER END USERS 257
11 GENE DELIVERY TECHNOLOGIES MARKET, BY REGION 261
11.1 INTRODUCTION 262
11.2 NORTH AMERICA 262
11.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 263
11.2.2 US 269
11.2.2.1 US to dominate North American market over forecast period 269
11.2.3 CANADA 274
11.2.3.1 Strong infrastructure and availability of funding for biomedical research to support market growth 274
11.3 EUROPE 279
11.3.1 EUROPE: MACROECONOMIC OUTLOOK 280
11.3.2 GERMANY 285
11.3.2.1 Germany to hold largest market share in Europe 285
 
11.3.3 UK 291
11.3.3.1 Increasing government funding to drive market growth 291
11.3.4 FRANCE 296
11.3.4.1 Rising support for genetic research to offer potential growth opportunities 296
11.3.5 ITALY 301
11.3.5.1 Rising R&D and support for gene delivery to drive market 301
11.3.6 SPAIN 306
11.3.6.1 Growing expansion of research centers to stimulate market 306
11.3.7 REST OF EUROPE 311
11.4 ASIA PACIFIC 316
11.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK 316
11.4.2 CHINA 323
11.4.2.1 Increasing R&D expenditure to drive market growth 323
11.4.3 JAPAN 328
11.4.3.1 Rising research into precision medicine to support market growth 328
11.4.4 INDIA 334
11.4.4.1 Strong research base and rising FDI in pharma sector to support market growth 334
11.4.5 SOUTH KOREA 339
11.4.5.1 Alliances & investments in research to drive market 339
11.4.6 AUSTRALIA 344
11.4.6.1 Increasing focus on precision medicine to offer significant growth opportunities 344
11.4.7 REST OF ASIA PACIFIC 349
11.5 LATIN AMERICA 354
11.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK 354
11.5.2 BRAZIL 360
11.5.2.1 Brazil to hold largest market share in LATAM 360
11.5.3 MEXICO 365
11.5.3.1 Strong pharmaceutical industry and increased government support to augment market growth 365
11.5.4 REST OF LATIN AMERICA 370
11.6 MIDDLE EAST 375
11.6.1 MIDDLE EAST: MACROECONOMIC OUTLOOK 375
11.6.2 GCC COUNTRIES 381
11.6.2.1 Saudi Arabia 386
11.6.2.1.1 Increasing government investments in healthcare and growing pharmaceuticals industry to support market 386
11.6.2.2 UAE 392
11.6.2.2.1 Growing R&D expenditure and infrastructural development to drive market 392
11.6.2.3 Rest of GCC Countries 397
11.6.3 REST OF MIDDLE EAST 403
11.7 AFRICA 408
11.7.1 RISING EMPHASIS ON GENE DELIVERY TECHNOLOGIES FOR THERAPEUTICS TO SUPPORT MARKET GROWTH 408
11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 409
12 COMPETITIVE LANDSCAPE 415
12.1 OVERVIEW 415
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 415
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN GENE DELIVERY TECHNOLOGIES MARKET 415
12.3 REVENUE ANALYSIS 417
12.4 MARKET SHARE ANALYSIS 417
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 419
12.5.1 STARS 419
12.5.2 EMERGING LEADERS 419
12.5.3 PERVASIVE PLAYERS 420
12.5.4 PARTICIPANTS 420
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 421
12.5.5.1 Company footprint 421
12.5.5.2 Region footprint 421
12.5.5.3 Product footprint 422
12.5.5.4 Method footprint 423
12.5.5.5 Application footprint 424
12.5.5.6 End-user footprint 425
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 425
12.6.1 PROGRESSIVE COMPANIES 425
12.6.2 RESPONSIVE COMPANIES 425
12.6.3 DYNAMIC COMPANIES 426
12.6.4 STARTING BLOCKS 426
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 427
12.7 COMPANY VALUATION & FINANCIAL METRICS 428
12.7.1 FINANCIAL METRICS 428
12.7.2 COMPANY VALUATION 428
12.8 BRAND/PRODUCT COMPARISON 429
12.9 COMPETITIVE SCENARIO 430
12.9.1 PRODUCT LAUNCHES 430
12.9.2 DEALS 431
12.9.3 EXPANSIONS 432
 
13 COMPANY PROFILES 433
13.1 KEY PLAYERS 433
13.1.1 THERMO FISHER SCIENTIFIC INC. 433
13.1.1.1 Business overview 433
13.1.1.2 Products/Services/Solutions offered 434
13.1.1.3 Recent developments 441
13.1.1.3.1 Product launches 441
13.1.1.3.2 Expansions 441
13.1.1.4 MnM view 441
13.1.1.4.1 Key strengths 441
13.1.1.4.2 Strategic choices 442
13.1.1.4.3 Weaknesses and competitive threats 442
13.1.2 DANAHER CORPORATION 443
13.1.2.1 Business overview 443
13.1.2.2 Products/Services/Solutions offered 444
13.1.2.3 Recent developments 446
13.1.2.3.1 Product launches 446
13.1.2.3.2 Deals 447
13.1.2.3.3 Expansions 447
13.1.2.4 MnM view 447
13.1.2.4.1 Key strengths 447
13.1.2.4.2 Strategic choices 448
13.1.2.4.3 Weaknesses and competitive threats 448
13.1.3 MERCK KGAA 449
13.1.3.1 Business overview 449
13.1.3.2 Products/Services/Solutions offered 450
13.1.3.3 Recent developments 453
13.1.3.3.1 Deals 453
13.1.3.3.2 Expansions 454
13.1.3.4 MnM view 454
13.1.3.4.1 Key strengths 454
13.1.3.4.2 Strategic choices 454
13.1.3.4.3 Weaknesses and competitive threats 454
13.1.4 BIO-RAD LABORATORIES, INC. 455
13.1.4.1 Business overview 455
13.1.4.2 Products/Services/Solutions offered 456
13.1.5 AGILENT TECHNOLOGIES, INC. 458
13.1.5.1 Business overview 458
13.1.5.2 Products/Services/Solutions offered 459
13.1.5.3 Recent developments 461
13.1.5.3.1 Deals 461
 
13.1.6 REVVITY 462
13.1.6.1 Business overview 462
13.1.6.2 Products/Services/Solutions offered 463
13.1.6.3 Recent developments 465
13.1.6.3.1 Product launches 465
13.1.6.3.2 Deals 465
13.1.7 QIAGEN 466
13.1.7.1 Business overview 466
13.1.7.2 Products/Services/Solutions offered 467
13.1.8 GENSCRIPT 469
13.1.8.1 Business overview 469
13.1.8.2 Products/Services/Solutions offered 470
13.1.8.3 Recent developments 471
13.1.8.3.1 Deals 471
13.1.9 TAKARA BIO INC. 472
13.1.9.1 Business overview 472
13.1.9.2 Products/Services/Solutions offered 473
13.1.9.3 Recent developments 479
13.1.9.3.1 Product launches 479
13.1.9.3.2 Deals 479
13.1.10 PROMEGA CORPORATION 480
13.1.10.1 Business overview 480
13.1.10.2 Products/Services/Solutions offered 480
13.1.11 BIO-TECHNE 482
13.1.11.1 Business overview 482
13.1.11.2 Products/Services/Solutions offered 483
13.1.11.3 Recent developments 485
13.1.11.3.1 Product launches 485
13.1.12 LONZA 486
13.1.12.1 Business overview 486
13.1.12.2 Products/Services/Solutions offered 487
13.1.12.3 Recent developments 489
13.1.12.3.1 Product launches 489
13.1.12.3.2 Deals 489
13.1.13 OXFORD BIOMEDICA PLC 490
13.1.13.1 Business overview 490
13.1.13.2 Products/Services/Solutions offered 491
13.1.13.3 Recent developments 492
13.1.13.3.1 Product launches 492
13.1.13.3.2 Deals 492
13.1.13.3.3 Other developments 493
 
13.1.14 SARTORIUS AG 494
13.1.14.1 Business overview 494
13.1.14.2 Products/Services/Solutions offered 495
13.1.14.3 Recent developments 497
13.1.14.3.1 Product launches 497
13.1.14.3.2 Deals 497
13.1.15 MAXCYTE 498
13.1.15.1 Business overview 498
13.1.15.2 Products/Services/Solutions offered 499
13.1.15.3 Recent developments 500
13.1.15.3.1 Deals 500
13.2 OTHER PLAYERS 503
13.2.1 CELL BIOLABS, INC. 503
13.2.2 GENTARGET INC. 505
13.2.3 ORIGENE TECHNOLOGIES, INC. 507
13.2.4 ALTOGEN BIOSYSTEMS 508
13.2.5 OZ BIOSCIENCES 510
13.2.6 GENECOPOEIA, INC. 512
13.2.7 CREATIVE BIOLABS 513
13.2.8 SYNBIO TECHNOLOGIES LLC 513
13.2.9 SYSTEM BIOSCIENCES, LLC 514
13.2.10 VECTORBUILDER INC. 515
14 APPENDIX 517
14.1 DISCUSSION GUIDE 517
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 521
14.3 CUSTOMIZATION OPTIONS 523
14.4 RELATED REPORTS 523
14.5 AUTHOR DETAILS 524